The French anti-doping agency (AFLD) has reportedly validated two aspects of its testing procedures used in the Floyd Landis case. According to L'Equipe, the first test related to the analysis of Landis' B-sample, taken after stage 17 of the 2006 Tour de France, while the second was an audit of the Isotope Ratio Mass Spectometry (IRMS) machine used to determine that Landis' samples contained synthetic testosterone.
"Following the attacks from the Landis camp, the AFLD took the initiative to require these two analyses," said AFLD president Pierre Bordry.
